Dystrophin-deficient cardiomyocytes derived from human urine: New biologic reagents for drug discovery

•We derived induced pluripotent stem cells (iPSCs) from human urine.•Duchenne Muscular Dystrophy (DMD) disease specific iPSCs were derived from urine.•DMD iPSCs were directed to form beating cardiomyocytes.•Physiological differences were observed between DMD and normal cardiomyocytes.•Disease-specific cardiomyocytes can be exploited for drug discovery.

The ability to extract somatic cells from a patient and reprogram them to pluripotency opens up new possibilities for personalized medicine. Induced pluripotent stem cells (iPSCs) have been employed to generate beating cardiomyocytes from a patient's skin or blood cells. Here, iPSC methods were used to generate cardiomyocytes starting from the urine of a patient with Duchenne muscular dystrophy (DMD). Urine was chosen as a starting material because it contains adult stem cells called urine-derived stem cells (USCs). USCs express the canonical reprogramming factors c-myc and klf4, and possess high telomerase activity. Pluripotency of urine-derived iPSC clones was confirmed by immunocytochemistry, RT-PCR and teratoma formation. Urine-derived iPSC clones generated from healthy volunteers and a DMD patient were differentiated into beating cardiomyocytes using a series of small molecules in monolayer culture. Results indicate that cardiomyocytes retain the DMD patient's dystrophin mutation. Physiological assays suggest that dystrophin-deficient cardiomyocytes possess phenotypic differences from normal cardiomyocytes. These results demonstrate the feasibility of generating cardiomyocytes from a urine sample and that urine-derived cardiomyocytes retain characteristic features that might be further exploited for mechanistic studies and drug discovery.

Graphical abstractFigure optionsDownload full-size imageDownload high-quality image (192 K)Download as PowerPoint slide